Riociguat + CilostazolUnknown
Clinical experience with co-administration of Adempas and other phosphodiesterase inhibitors (for example, milrinone, cilostazole, roflumilast) is limited.
Source: FDA drug label - riociguat
Riociguat Interactions
Brand names: Adempas
Soluble Guanylate Cyclase Stimulator · Guanylate Cyclase Stimulators
FDA Black Box Warning
WARNING: EMBRYO-FETAL TOXICITY Do not administer Adempas to a pregnant female because it may cause fetal harm [see Contraindications ( 4.1 ), Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.1 , 5.2 ),and Use in Specific Populations ( 8.3 )]. For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program [see Warnings and Precautions ( 5.1 , 5.2 )]. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. • Do not administer Adempas to a pregnant female because it may cause fetal harm. ( 4.1 , 5.1 , 8.1 ) • Females of reproductive potential: Exclude pregnancy before start of treatment, monthly during treatment, and 1 month after treatment discontinuation. Prevent pregnancy during treatment and for one month after treatment discontinuation by use of effective forms of contraception. ( 2.3 , 5.1, 5.2 , 8.6 ) • For females, Adempas is available only through a restricted program called the Adempas REMS Program. ( 5.1, 5.2 )
4 interactions on record
Riociguat + ItraconazoleUnknown
Strong CYP and P-gp/BCRP inhibitors: Concomitant use of riociguat with strong cytochrome CYP inhibitors and P-gp/BCRP inhibitors such as azole antimycotics (for example, ketoconazole, itraconazole) or HIV protease inhibitors (such as ritonavir) increase riociguat exposure and may result in hypotension.
Source: FDA drug label - riociguat
Riociguat + KetoconazoleUnknown
Strong CYP and P-gp/BCRP inhibitors: Concomitant use of riociguat with strong cytochrome CYP inhibitors and P-gp/BCRP inhibitors such as azole antimycotics (for example, ketoconazole, itraconazole) or HIV protease inhibitors (such as ritonavir) increase riociguat exposure and may result in hypotension.
Source: FDA drug label - riociguat
Riociguat + RitonavirUnknown
Strong CYP and P-gp/BCRP inhibitors: Concomitant use of riociguat with strong cytochrome CYP inhibitors and P-gp/BCRP inhibitors such as azole antimycotics (for example, ketoconazole, itraconazole) or HIV protease inhibitors (such as ritonavir) increase riociguat exposure and may result in hypotension.
Source: FDA drug label - riociguat